Company profile
Pro-Dex, Inc.
NASDAQ: PDEX · Healthcare · Medical - Instruments & Supplies
#398 of 1,418 Healthcare companies by revenue69th-percentile growth
EA Score
86AFH 87DQ 91GM 75SS 80
v0.1 · 65/100 weight · provisional
↑ listing tenure, filing timeliness · ↓ balance-sheet leverage, 3-yr revenue growth
Methodology →Revenue TTM
$74.6M
Rev growth YoY (TTM)
+16.4%
Net income (FY)
$9.0M
Employees
180
as of 2026-08-14
Market cap
$216.8M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$66.6M$66.6M2025
Net income$9.0M$9.0M2025
Operating income$10.7M$10.7M2025
Total assets$61.2M$61.2M2025
Liabilities$24.6M$24.6M2025
Equity$36.6M$36.6M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Pro-Dex, Inc.’s revenue?
Pro-Dex, Inc. booked $66.6M in FY2025 revenue, growing 24% year over year — faster than most Healthcare companies we track, at a 13.5% net margin.
Peers · Healthcare
Intellia Therapeutics, Inc.57CKura Oncology, Inc.39DPraxsyn Corporation——Exagen Inc.55CAytu BioPharma, Inc.53DEnanta Pharmaceuticals, Inc.55CNeighbors
Orange →Key facts
CEORichard Lee Van Kirk Jr.
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersIrvine, CA
ExchangeNASDAQ: PDEX
Employees180
IPO date1986-08-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.